MMED (Minimed Group) Other Long-Term Liabilities: $317 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MMED Minimed Group Inc MMED
15 GF Score
Price $19.85
! 3 Warning Signs
View Full Analysis

What is Minimed Group Other Long-Term Liabilities?

Minimed Group MMED +1.77% 15 Other Long-Term Liabilities is $317 Mil as of Apr. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

Minimed Group's other long-term liabilities for the quarter that ended in Apr. 2026 was $317 Mil.

Minimed Group's quarterly other long-term liabilities increased from Oct. 2025 ($141 Mil) to Jan. 2026 ($184 Mil) and increased from Jan. 2026 ($184 Mil) to Apr. 2026 ($317 Mil).

Minimed Group's annual other long-term liabilities increased from Apr. 2024 ($128 Mil) to Apr. 2025 ($160 Mil) and increased from Apr. 2025 ($160 Mil) to Apr. 2026 ($317 Mil).

Minimed Group Other Long-Term Liabilities Related Terms

Minimed Group Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Minimed Group's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group Other Long-Term Liabilities Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25 Apr26
Other Long-Term Liabilities
0.00 128.00 160.00 317.00

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26 Apr26
Other Long-Term Liabilities Get a 7-Day Free Trial 0.00 160.00 141.00 184.00 317.00
MMED
15GF Score
Minimed Group Inc MMED
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $317 Mil mean?
Minimed Group (MMED) has a Other Long-Term Liabilities of $317 Mil as of Apr. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Minimed Group and its competitors.
Is Minimed Group's Other Long-Term Liabilities too high?
Minimed Group's current Other Long-Term Liabilities is $317 Mil. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's Other Long-Term Liabilities compare to MMSI and NVST?
Minimed Group's Other Long-Term Liabilities of $317 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Minimed Group and its competitors. Minimed Group's current Other Long-Term Liabilities is $317 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current Other Long-Term Liabilities of $317 Mil. The current Other Long-Term Liabilities is $317 Mil. Minimed Group's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Minimed Group (MMED), the current Other Long-Term Liabilities is $317 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges B8S:Germany
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score

Get the complete analysis for MMED

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.85
Price